Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04551898 · ClinicalTrials.gov registry record · Phase 2
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
A Phase 2 study of COVID-19, sponsored by BeiGene.
- Completed
- Registry status
- Phase 2
- Development phase
- 181
- Enrollment target
- 18
- Study locations
NCT04551898: Completed Phase 2 study of COVID-19, sponsored by BeiGene.
NCT04551898 is a Phase 2 study of COVID-19 that has completed, run by BeiGene. The registered enrollment target is 181 participants, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 18 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04551898, a Phase 2 study of COVID-19, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 181 participants
- Enrollment target
- 18
- Study locations
Study Summary
The primary objective of this study is to evaluate the efficacy of BGB-DXP593 administered intravenously as a single dose in participants with mild to moderate COVID-19
Primary Outcome
SARS-CoV-2 viral shedding was measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal swab samples.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BGB-DXP593
Study Locations (18)
Florida
- Btc Network Midland Florida Clinical Research Center - DeLand
- Elixia Clinical Research Collaborative - Hollywood
- Homestead Associates in Research Inc - Miami
- Medical Research Center of Miami Ii, Inc - Miami
- Us Associates in Research - Miami
- Continental Research Network - Miami
- Orlando Health Ufhealth Cancer Center - Orlando
Other
- Hospital Das Clinicas Da Faculdade de Medicina de Botucatu - Botucatu
- Fundacao Universidade de Caxias Do Sul - Caxias do Sul
- Consultoria Medica E Pesquisa Clinica - Sorcaba
- Hospital Cardiologica Aguascalientes - Aguascalientes
- IECSI - Monterrey
- Task Clinical Research Centre - Cape Town
- Langeberg Clinical Trials - Cape Town
Michigan
- Revive Research Institute - Dearborn
- Revival Research Institute Farmington Hills - Sterling Heights
Texas
- Amarillo Center For Clinical Research - Amarillo
- Panamerican Clinical Research Us Headquarters - Brownsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2020-12-02 |
| Est. Completion | 2021-05-25 |
| Phase | Phase 2 |
What the finished NCT04551898 record still lists
NCT04551898 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04551898 lists 18 locations in 4 states (Florida, Other, Michigan).
Frequently Asked Questions
What is clinical trial NCT04551898 about?
NCT04551898 is a clinical study titled "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)". The primary objective of this study is to evaluate the efficacy of BGB-DXP593 administered intravenously as a single dose in participants with mild to moderate COVID-19
What is the current status of trial NCT04551898?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 181 participants. The study started on 2020-12-02. Estimated completion is 2021-05-25.
What conditions does trial NCT04551898 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT04551898?
The interventions under investigation include: Placebo (DRUG), BGB-DXP593 (DRUG).
Who is sponsoring clinical trial NCT04551898?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04551898 being conducted?
This trial has 18 study locations across Florida, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04551898's enrollment target sits among peer trials
181 162nd of 298 higher than 137 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI